STOP-HCV is a Medical Research Council (MRC) funded consortium which aims to use patient information to establish the most effective and cost effective treatments for patients with Hepatitis C Virus.
The STOP-HCV consortium is formed of 21 partners representing academia, industry and the Hepatitis C Trust.
How to prioritise high-cost HCV treatment? - STOP-HCV investigator Natasha Martin, and others, address this question in an article in the Journal of Hepatology.
STOP-HCV-1 - STOP-HCV investigator, Dr Graham Cooke, has secured funding from the NIHR Efficacy and Mechanism Evaluation programme to undertake a clinical study (STOP-HCV-1) to look at stratification within short-course, all-oral direct-acting antiviral HCV treatment regimes, for Gt1 HCV infected patients with mild liver disease.
High-throughput whole-genome HCV sequencing - STOP-HCV researchers have published a method for high-throughput detection of HCV, and other diverse pathogens, in F1000Research (13 October 2015). This enrichment probe based method provides efficient detection and sequencing of any HCV genome, including mixtures and intra-host variants, in a single experiment.
Gilead Sciences BOSON study - exciting clinical results from the BOSON study - an academic/industrial collaboration within STOP-HCV - have been published online (03 August 2015) in Gastroenterology.
July/August 2015 - STOP-HCV researchers Dr John McLauchlan and Dr Graham Cooke comment on the work of STOP-HCV, and the current treatment landscape for HCV, in pieces published by the MRC and Medicine at Imperial.